<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49620">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460250</url>
  </required_header>
  <id_info>
    <org_study_id>I12033 FIBROSCAME</org_study_id>
    <nct_id>NCT02460250</nct_id>
  </id_info>
  <brief_title>Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death</brief_title>
  <acronym>FIBROSCAME</acronym>
  <official_title>Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the French Biomedicine Agency annual report on retrieval activities and
      transplants, 1,164 liver transplants were performed in 2011 and 1,161 in 2012. If the amount
      of brain death donors and retrieved liver grafts appears relatively stable, it remains
      clearly insufficient compared to the increasing number of patients on the waiting list for
      liver transplantation (2,462 in 2011). The median time on the waiting list before liver
      transplantation which was established from the cohort of patients registered between 2007
      and 2011 (excluding patients registered for emergency transplantation and for living
      related-donor transplantation) increased significantly from 4.4 months between 2007 and 2009
      to 6.6 months between 2010 and 2011. In order to compensate for the lack of liver grafts,
      donors acceptance criteria were broadened. For example, alternative transplantation lists
      were created with liver grafts coming from so-called &quot;marginal&quot; donors. However, despite
      these efforts, livers were retrieved on only two out of three brain death donors, i.e. in
      1,572 and 1,589 organ donors in 2011 and 2012, respectively. This is unfortunately not
      enough to meet the increasing needs in liver grafts and a growing number of patients wait
      each year for transplant. Strategic lines of improvement were defined in order to meet the
      &quot;2012-2016 transplant perspective&quot; which targets 5,700 transplants carried out in 2015 (+5%
      every year, all transplants included, with 5,023 transplants in 2012).

      According to the last consensus conference on liver transplantation of the HAS (French High
      Authority of Health) the assessment of the degree of macrovacuolar and microvacuolar
      steatosis determines the possibility to retrieve the graft or not. Liver steatosis consists
      in an accumulation of fatty droplets in hepatocytes. Its prevalence is high, ranging from
      16% to 31% in the general population, and increases up to 46% in heavy drinkers and to
      50-80% in the obese population. Steatosis results mostly from alcohol consumption and from
      metabolic syndrome (obesity, type 2 diabetes, hypertriglyceridemia) called non-alcoholic
      fatty liver disease (NAFLD), and is more rarely secondary to viral hepatitis or exposure to
      certain medications. NAFLD involves up to 30% of the population in Western countries and its
      prevalence is increasing. NAFLD may lead to asymptomatic steatosis, but also to
      steatohepatitis or advanced fibrosis including cirrhosis and its complications Accordingly,
      the improvement of liver grafts selection based on objective quantitative criteria which
      takes into account the degree of liver steatosis appears crucial to increase the number of
      hepatic transplants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medical procedure: Fibroscan® based on vibration control transient elastography (VCTETM)
      with evaluation of controlled attenuation parameter (CAP™) by ultrasounds (Echosens, Paris,
      France).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Controlled Attenuation Parameter™ (CAP™) measurement</measure>
    <time_frame>1 Day</time_frame>
    <description>Evaluation of the diagnostic accuracy of the CAP™ measured with Fibroscan® to objectively reflect the degree of liver steatosis, a parameter which can be used as an aid in selecting liver grafts before retrieval in donors with brain death (DBD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver Stiffness (LS) measurement</measure>
    <time_frame>1 Day</time_frame>
    <description>Evaluation of the diagnostic accuracy of LS measured with Fibroscan® to objectively reflect the degree of fibrosis and steatosis, a parameter which can be used as an aid in selecting liver grafts before retrieval in DBD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Controlled Attenuation Parameter™ (CAP™) measurement</measure>
    <time_frame>1 week</time_frame>
    <description>Determination of the prognostic value of CAP™ in terms of survival of liver grafts at one week after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Stiffness (LS) measurement</measure>
    <time_frame>1 week</time_frame>
    <description>Determination of the prognostic value of LS in terms of survival of liver grafts at one week after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Stiffness (LS) measurement</measure>
    <time_frame>1 month</time_frame>
    <description>Determination of the prognostic value of LS in terms of survival of liver grafts at one month after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Controlled Attenuation Parameter™ (CAP™) measurement</measure>
    <time_frame>1 month</time_frame>
    <description>Determination of the prognostic value of CAP™ in terms of survival of liver grafts at one month after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Stiffness (LS) measurement</measure>
    <time_frame>1 year</time_frame>
    <description>Determination of the prognostic value of LS in terms of survival of liver grafts at one week, one month and one year after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Controlled Attenuation Parameter™ (CAP™) measurement</measure>
    <time_frame>1 year</time_frame>
    <description>Determination of the prognostic value of CAP™ in terms of survival of liver grafts at one week, one month and one year after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis measurement</measure>
    <time_frame>1 Day</time_frame>
    <description>evaluate the diagnostic a accuracy of FibroTest in selecting liver grafts before retrieval in DBD by comparing with 1) histological data obtained with liver biopsy (degree of steatosis, degree of fibrosis) and with 2) CAPTM/LS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steatosis measurement</measure>
    <time_frame>1 Day</time_frame>
    <description>evaluate the diagnostic a accuracy of SteatoTest in selecting liver grafts before retrieval in DBD by comparing with 1) histological data obtained with liver biopsy (degree of steatosis, degree of fibrosis) and with 2) CAPTM/LS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis measurement</measure>
    <time_frame>1 month</time_frame>
    <description>Determination of the short-term prognostic values of FibroTest in terms of survival of liver grafts at one month after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steatosis measurement</measure>
    <time_frame>1 month</time_frame>
    <description>Determination of the short-term prognostic values of SteatoTest in terms of survival of liver grafts at one month after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis measurement</measure>
    <time_frame>1 year</time_frame>
    <description>Determination of the short-term prognostic values of FibroTest in terms of survival of liver grafts at one year after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steatosis measurement</measure>
    <time_frame>1 year</time_frame>
    <description>Determination of the short-term prognostic values of SteatoTest in terms of survival of liver grafts at one year after transplantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">740</enrollment>
  <condition>Tissue and Organ Harvesting</condition>
  <condition>Liver Transplantation</condition>
  <condition>Brain Death</condition>
  <arm_group>
    <arm_group_label>Fibroscan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked. Liver recipients will be followed up during one year. Biological and medical data used by all transplant sites for the follow-up of transplant patient will be collected</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fibroscan</intervention_name>
    <description>All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.</description>
    <arm_group_label>Fibroscan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years with recognized clinical brain death confirmed by
             clinical examination, who are considered for organ retrieval and clinically stable to
             achieve the retrieval procedure

        Exclusion Criteria:

          -  Personal objection to organ retrieval and clinical research expressed during lifetime
             and registered in the Registre National des Refus (French registration of all
             refusals to organ donation)

          -  Family objection to liver retrieval after donor's death

          -  Ongoing pregnancy when brain death is declared

          -  For FT and ST measurements included in the panel FibroMaxTM, 4 exclusion criteria are
             defined specifically (Acute hepatitis or cytolysis with ALT higher than 622 IU/L,
             acute or chronic hemolysis, extrahepatic cholestasis, sepsis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas PICHON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas PICHON, MD</last_name>
    <phone>+33555056240</phone>
    <email>nicolas.pichon@chu-limoges.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul BOURZEIX, MD</last_name>
    <phone>+3355558841</phone>
    <email>paul.bourzeix@chu-limoges.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martial OUENDO, MD</last_name>
      <phone>+33322668375</phone>
      <email>ouendo.martial@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Martial OUENDO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick JEANJEAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hervé DUPONT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent DUBE, MD</last_name>
      <phone>+33241353635</phone>
      <email>LaDube@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent DUBE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul CALES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc PIERROT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine VERDY, MD</last_name>
      <phone>+33381668515</phone>
      <email>sverdy@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Sabine VERDY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles CAPELLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien PILI FLOURY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent DI MARTINO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaël PITON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan PAILLOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine NEAU-CRANSAC, MD</last_name>
      <phone>+33556795522</phone>
      <email>martine.neau-cransac@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Martine NEAU-CRANSAC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien ROGIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Henri BERNARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victor DE LEDHINGEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe REVEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seddik SID AHMED, MD</last_name>
      <phone>+33298145243</phone>
      <email>seddik.sid-ahmed@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Baptiste NOUSBAUM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seddik SID AHMED, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwénaël PRAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier HUET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Estaing University Hospital</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>AP-HP Henri MONDOR</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe COMPAGNON, MD</last_name>
      <phone>+33149814205</phone>
      <email>philippe.compagnon@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe COMPAGNON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexis LAURENT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe DUVOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc PADILLA, MD</last_name>
      <phone>+33476768903</phone>
      <phone_ext>65523</phone_ext>
      <email>vleroy@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent LEROY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc PADILLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Noëlle HILLERET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien DHARANCY, MD</last_name>
      <phone>+33320445597</phone>
      <email>sebastien.dharancy@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Sébastien DHARANCY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas PICHON, MD</last_name>
      <phone>+33555056240</phone>
      <email>nicolas.pichon@chu-limoges.fr</email>
    </contact>
    <contact_backup>
      <last_name>Paul BOURZEIX</last_name>
      <phone>+33555058841</phone>
      <email>paul.bourzeix@chu-limoges.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolas PICHON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique LOUSTAUD-RATTI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno FRANCOIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe VIGNON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle BEGOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire MANCIA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas DAIX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Croix Rousse Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud GREGOIRE, MD</last_name>
      <email>gregoirear@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud GREGOIRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme DUMORTIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie RADENNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nice University Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodolphe Anty, MD</last_name>
      <phone>+33492035943</phone>
      <email>anty.r@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Rodolphe Anty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Jambou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe Orban, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Kremlin Bicêtre</name>
      <address>
        <city>Paris</city>
        <zip>84270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaëlle CHEISSON, MD</last_name>
      <phone>145213441</phone>
      <phone_ext>+33</phone_ext>
      <email>gaelle.cheisson@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Gaëlle CHEISSON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anatole HARROIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard VIGUE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques DURANTEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume DUBREUIL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Etienne LEBLANC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurore RODRIGUES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Rym HAMADA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas KERFORNE, MD</last_name>
      <email>t.kerforne@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>René ROBERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire DAYOT FIZELIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel PINSARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine SILVAIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine CHAGNEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas KERFORNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univesity Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronique REITER-CHENEL, MD</last_name>
      <phone>+33326784958</phone>
      <email>vreiter@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Veronique REITER-CHENEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra HEURGUE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain LEON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel RAYAR, MD</last_name>
      <phone>+33299284321</phone>
      <email>michel.rayar@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Michel RAYAR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marianne LATOURNERIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe CAMUS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ephrem SALAME, MD</last_name>
      <phone>+33247475937</phone>
      <email>e.salame@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Ephrem SALAME, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-François DEQUIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric PATAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Christophe VENHARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle MERCIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laetitia BODET-CONTENTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis GAROT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle ROUVE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youenn JOUAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie MANKIKIAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan EHRMANN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine GUILLON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annick LEGRAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte SALMON-GANDONNIERE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène GREGOIRE, MD</last_name>
      <phone>+3383154966</phone>
      <email>H.gregoire@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Jean François PERRIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène GREGOIRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaittha MUNAGAMAGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>May 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tissue and Organ Harvesting</keyword>
  <keyword>Liver graft</keyword>
  <keyword>Brain Death</keyword>
  <keyword>FibroScan®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Death</mesh_term>
    <mesh_term>Brain Death</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
